Loading clinical trials...
Loading clinical trials...
Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
Conditions
Interventions
lanreotide (Autogel formulation)
Locations
25
United States
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
UZ Antwerpen
Antwerp, Belgium
UCL Saint Luc
Brussels, Belgium
Fakultni nemocnice Na Bulovce
Prague, Czechia
General faculty
Prague, Czechia
Start Date
February 1, 2009
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
October 12, 2022
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions